{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T06:12:49Z","timestamp":1784182369030,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>HS-10353 is a novel positive allosteric modulator of \u03b3-aminobutyric acid A receptors that is under development for the treatment of major depressive disorder (MDD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a double-blind, randomized, placebo-controlled, phase 1 trial comprising single ascending dose (SAD) and multiple ascending dose (MAD) parts. In SAD, 8 healthy volunteers of each cohort were randomized (6:2) to receive HS-10353 (2\u201355\u2009mg) or placebo in a fasted state. In MAD, 12 MDD patients of each cohort were randomized (9:3) to receive HS-10353 (15\u201365\u2009mg\/day given for up to 7 days) or placebo. The primary objective was to assess the safety and tolerability of HS-10353. The efficacy endpoint in the MAD part included the change in the total score of the 17-item Hamilton Rating Scale for Depression (HAM-D17) at day 8. Pharmacokinetic (PK) analysis was performed as a secondary objective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty-eight healthy participants and forty-eight MDD participants completed the study. The most frequently observed treatment emergent adverse events (TEAEs) in the HS-10353 dose groups (occurring in \u2265\u20093 cases) included white blood cells urine positive and alanine aminotransferase increased in the SAD part, white blood cell count decreased and somnolence in the MAD part. All adverse events (AEs) were mild to moderate, and there were no serious adverse events or AEs that led to withdrawal from the trial. Treatment with 50\u2009mg of HS-10353 for only 7 days showed therapeutic effects, with a difference of -4.7 (95% CI: -8.9 to -0.5) in change from baseline of HAM-D17 score on day 8 compared to placebo. HS-10353 exhibited a terminal half-life of 14 to 22\u2009h with minimal accumulation upon repeat dosing (approximately 1.3- to 2.5-fold), supporting once-daily dosing; while absorption saturation was observed at fasting dose levels greater than 45\u2009mg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Single and multiple oral doses of HS-10353 were safe and well tolerated with a favorable PK profile. The findings in this small, short duration study suggest an early signal in patients with MDD that should be further investigated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>The trial is registered at China Drug Trials (CTR20210105, 2021-01-21) and ClinicalTrials.gov (NCT05195203, 2022-01-13).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-026-04926-5","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T14:05:10Z","timestamp":1779372310000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase 1 randomized trial of HS-10353, a novel GABA(A) positive allosteric modulator for treatment of major depressive disorder"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8789-4219","authenticated-orcid":false,"given":"Zhenlei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huali","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fude","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0238-6085","authenticated-orcid":false,"given":"Qi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"4926_CR1","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1016\/S0140-6736(18)31948-2","volume":"392","author":"GS Malhi","year":"2018","unstructured":"Malhi GS, Mann JJ. Depression. Lancet. 2018;392:2299\u2013312.","journal-title":"Lancet"},{"key":"4926_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115450","volume":"328","author":"J Zou","year":"2023","unstructured":"Zou J, Yang L, Yang G, Gao J. The efficacy and safety of some new GABAkines for treatment of depression: A systematic review and meta-analysis from randomized controlled trials. Psychiatry Res. 2023;328:115450.","journal-title":"Psychiatry Res"},{"key":"4926_CR3","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.tips.2023.06.009","volume":"44","author":"B Luscher","year":"2023","unstructured":"Luscher B, Maguire JL, Rudolph U, Sibille E. GABA(A) receptors as targets for treating affective and cognitive symptoms of depression. Trends Pharmacol Sci. 2023;44:586\u2013600.","journal-title":"Trends Pharmacol Sci"},{"key":"4926_CR4","doi-asserted-by":"publisher","first-page":"e072415","DOI":"10.1136\/bmj-2022-072415","volume":"380","author":"GE Ferreira","year":"2023","unstructured":"Ferreira GE, Abdel-Shaheed C, Underwood M, Finnerup NB, Day RO, McLachlan A, et al. Efficacy, safety, and tolerability of antidepressants for pain in adults: overview of systematic reviews. Bmj. 2023;380:e072415.","journal-title":"Bmj"},{"key":"4926_CR5","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1001\/jamapsychiatry.2025.1317","volume":"82","author":"A Janik","year":"2025","unstructured":"Janik A, Qiu X, Lane R, Popova V, Drevets WC, Canuso CM, et al. Esketamine monotherapy in adults with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2025;82:877\u201387.","journal-title":"JAMA Psychiatry"},{"key":"4926_CR6","unstructured":"J Pharmaceuticals. SPRAVATO (esketamine) nasal spray[package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/211243s019lbl.pdf. Revised April 2025. Accessed April 16, 2026."},{"key":"4926_CR7","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1056\/NEJMoa1815981","volume":"381","author":"H Gunduz-Bruce","year":"2019","unstructured":"Gunduz-Bruce H, Silber C, Kaul I, Rothschild AJ, Riesenberg R, Sankoh AJ, et al. Trial of SAGE-217 in patients with major depressive disorder. N Engl J Med. 2019;381:903\u201311.","journal-title":"N Engl J Med"},{"key":"4926_CR8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s00213-006-0313-7","volume":"186","author":"CN Epperson","year":"2006","unstructured":"Epperson CN, Gueorguieva R, Czarkowski KA, Stiklus S, Sellers E, Krystal JH, et al. Preliminary evidence of reduced occipital GABA concentrations in puerperal women: a 1H-MRS study. Psychopharmacology (Berl). 2006;186:425\u201333.","journal-title":"Psychopharmacology (Berl)"},{"key":"4926_CR9","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00228-009-0650-7","volume":"65","author":"E K\u00fc\u00e7\u00fckibrahimo\u011flu","year":"2009","unstructured":"K\u00fc\u00e7\u00fckibrahimo\u011flu E, Saygin MZ, Cali\u015fkan M, Kaplan OK, Unsal C, G\u00f6ren MZ. The change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression. Eur J Clin Pharmacol. 2009;65:571\u20137.","journal-title":"Eur J Clin Pharmacol"},{"key":"4926_CR10","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1001\/archpsyc.64.2.193","volume":"64","author":"G Hasler","year":"2007","unstructured":"Hasler G, van der Veen JW, Tumonis T, Meyers N, Shen J, Drevets WC. Reduced prefrontal glutamate\/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 2007;64:193\u2013200.","journal-title":"Arch Gen Psychiatry"},{"key":"4926_CR11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/mp.2010.120","volume":"16","author":"B Luscher","year":"2011","unstructured":"Luscher B, Shen Q, Sahir N. The GABAergic deficit hypothesis of major depressive disorder. Mol Psychiatry. 2011;16:383\u2013406.","journal-title":"Mol Psychiatry"},{"key":"4926_CR12","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/s41583-023-00724-7","volume":"24","author":"W Koh","year":"2023","unstructured":"Koh W, Kwak H, Cheong E, Lee CJ. GABA tone regulation and its cognitive functions in the brain. Nat Rev Neurosci. 2023;24:523\u201339.","journal-title":"Nat Rev Neurosci"},{"key":"4926_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02514-2","volume":"13","author":"AJ Cutler","year":"2023","unstructured":"Cutler AJ, Mattingly GW, Maletic V. Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder. Transl Psychiatry. 2023;13:228.","journal-title":"Transl Psychiatry"},{"key":"4926_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/1060028019873320","volume":"54","author":"JG Powell","year":"2020","unstructured":"Powell JG, Garland S, Preston K, Piszczatoski C. Brexanolone (Zulresso): finally, an FDA-approved treatment for postpartum depression. Ann Pharmacother. 2020;54:157\u201363.","journal-title":"Ann Pharmacother"},{"key":"4926_CR15","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1007\/s00213-023-06427-2","volume":"240","author":"DS Reddy","year":"2023","unstructured":"Reddy DS, Mbilinyi RH, Estes E. Preclinical and clinical pharmacology of brexanolone (allopregnanolone) for postpartum depression: a landmark journey from concept to clinic in neurosteroid replacement therapy. Psychopharmacology (Berl). 2023;240:1841\u201363.","journal-title":"Psychopharmacology (Berl)"},{"key":"4926_CR16","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1176\/appi.ajp.20220785","volume":"180","author":"KM Deligiannidis","year":"2023","unstructured":"Deligiannidis KM, Meltzer-Brody S, Maximos B, Peeper EQ, Freeman M, Lasser R, et al. Zuranolone for the treatment of postpartum depression. Am J Psychiatry. 2023;180:668\u201375.","journal-title":"Am J Psychiatry"},{"key":"4926_CR17","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/pcn.13917","volume":"80","author":"M Kato","year":"2026","unstructured":"Kato M, Nakagome K, Baba T, Sonoyama T, Fukuju H, Shimizu R, et al. Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: a double-blind, randomized, placebo-controlled, phase 3 clinical trial. Psychiatry Clin Neurosci. 2026;80:76\u201386.","journal-title":"Psychiatry Clin Neurosci"},{"key":"4926_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115640","volume":"331","author":"Z Li","year":"2024","unstructured":"Li Z, Wu Q, Peng P, Wu M, Liu S, Liu T. Efficacy and safety of zuranolone for the treatment of depression: a systematic review and meta-analysis. Psychiatry Res. 2024;331:115640.","journal-title":"Psychiatry Res"},{"key":"4926_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2024.1361692","volume":"18","author":"A Ahmad","year":"2024","unstructured":"Ahmad A, Awan AR, Nadeem N, Javed AS, Farooqi M, Daniyal M, et al. Zuranolone for treatment of major depressive disorder: a systematic review and meta-analysis. Front Neurosci. 2024;18:1361692.","journal-title":"Front Neurosci"},{"key":"4926_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1425295","volume":"15","author":"A Raja","year":"2024","unstructured":"Raja A, Ahmed S, Basit Ali Siddiqui M, Lamiya Mir S, Kumar R, Ahmed M, et al. Evaluating the safety and efficacy of zuranolone in the management of major depressive disorder and postpartum depression, with or without concurrent insomnia: a rigorous systematic review and meta-analysis. Front Psychiatry. 2024;15:1425295.","journal-title":"Front Psychiatry"},{"key":"4926_CR21","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1089\/jwh.2023.0991","volume":"33","author":"ZM Diaz","year":"2024","unstructured":"Diaz ZM, Adashi EY. Zuranolone: a breakthrough in the treatment of postpartum depression. J Womens Health (Larchmt). 2024;33:407\u20138.","journal-title":"J Womens Health (Larchmt)"},{"key":"4926_CR22","unstructured":"Washington D Diagnostic and statistical manual of mental disorders, 5th edition. 2013"},{"key":"4926_CR23","first-page":"22","volume":"59","author":"DV Sheehan","year":"1998","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59:22\u201333. quiz 4\u201357","journal-title":"J Clin Psychiatry"},{"key":"4926_CR24","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41386-023-01728-8","volume":"49","author":"SM Thompson","year":"2024","unstructured":"Thompson SM. Modulators of GABA(A) receptor-mediated inhibition in the treatment of neuropsychiatric disorders: past, present, and future. Neuropsychopharmacology. 2024;49:83\u201395.","journal-title":"Neuropsychopharmacology"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-04926-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04926-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04926-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:58:42Z","timestamp":1784181522000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-04926-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4926"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-04926-5","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This clinical trial was approved by the Ethics Committee of West China Hospital (Ethics Approval Number: 2020 Clinical Trial [Western Medicine] Review 216). Informed consent was provided by all recruited subjects prior to the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HZ is a current employee of Shanghai Hansoh BioMedical Co., Ltd., JQ and YT are former employees. Other authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"399"}}